Wellvax · Investor presentation 2026
Advanced chemistry.
Unlocking production potential.
Proprietary oilfield scale-removal systems. An integrated platform spanning formulation, contract manufacturing and delivery, built to serve recurring treatment demand.
Wellvax · Investor presentation 2026
Targeted technology. Repeatable commercial demand.
A recurring operating need
Mineral scale restricts flow and reaccumulates over time. Treatment demand is linked to well conditions and ongoing production maintenance.
Integrated delivery
Control of formulation, contract manufacturing and delivery supports a transaction-based model, with chemicals sold by litre per treatment.
Source: supplied 2026 investor deck, pp. 2 and 7–9. Model assumptions: five treatments per month, one chemical and 25,000 litres per treatment. These are modelled figures, not reported revenue.
Wellvax · Investor presentation 2026
Three systems. Explore the chemistry in 3D.
Drag to rotate. Select a formulation. Activate the treatment to explore how targeted scale removal works.
Acid-based system
DuoSolve-D
Carbonates · Anhydrite · Sulfates
Single-stage treatment dissolves carbonate and sulfate scale together, eliminating separate acid and chelant cycles.
For rapid scale removal where well metallurgy permits acid treatment.
Select a product or tap a drum to discover its application.
Illustrative field view · Not a company deployment
Play with the field. Explore the opportunity.
Wellvax · Investor presentation 2026
Four active markets. A platform for expansion.
United States · Texas
Commercial presence targeting operators in the Permian Basin and Gulf Coast.
Venezuela
Commercial presence in mature basins with recurring mineral-scale challenges.
Ecuador
Commercial engagement with national and independent producers.
Mexico
Research, formulation and operations anchoring the commercial platform.
Letters of intent are in place across these four markets. They will be provided as negotiations advance and an NDA is signed.
Expansion priorities include Saudi Arabia and other GCC markets, followed by Africa.
Wellvax · Investor presentation 2026
Engineered for challenging well conditions.
Targeted mineral removal
Three systems address carbonates, anhydrite, sulfates and barite. Formulation selection follows scale mineralogy and well metallurgy.
Laboratory performance
The technical sheets describe static dissolution, high-pressure/high-temperature, corrosion-coupon and crude-compatibility testing, with effectiveness up to 130°C.
Metallurgical compatibility
The alkaline systems provide a controlled-corrosion option for carbon steel, 13Cr, duplex stainless steel and corrosion-resistant alloy completions.
Expanded testing program
Planned Louisiana laboratory validation and testing budget: more than USD 100,000, with scope defined by the products and tests included.
Technical performance summarized from the supplied product sheets. Laboratory findings describe test conditions; field application is selected for each well.
Wellvax · Investor presentation 2026
A transaction-based revenue engine.
Chemicals sold per litre
Revenue is linked to the chemical volume delivered for each treatment. Scale reaccumulation creates repeat-treatment opportunities.
Advance-funded formulation
The investor deck describes a 50–60% customer advance before formulation, reducing working-capital needs and collection exposure.
Flexible field application
Bullhead injection, coiled tubing, batch soaking, recirculation, continuous circulation and squeeze application fit existing operating workflows.
Potential additional upside
Production-linked participation may be negotiated with individual customers.
The base model uses an estimated USD 12 per litre. Actual pricing varies with volume, frequency, formulation and chemical type.
Wellvax · Investor presentation 2026
USD 2 million to accelerate commercial expansion.
Deploy targeted oilfield chemistry across established commercial markets, expand technical capacity and build the organization for scale.
Per-treatment model: USD 300,000 revenue less USD 120,000 cost of goods. Gross profit is before operating expenses and tax. Investment terms are subject to definitive documentation.
Wellvax · Investor presentation 2026
Invest in the company. Expand its reach.
Testing and validation
Fund product testing and laboratory programs. The planned Louisiana program is budgeted at more than USD 100,000, depending on the product and test scope.
Technical team growth
Hire engineers, technicians and additional personnel to support product application, technical delivery and business growth.
Offices and company deployment
Establish and equip offices, strengthen operations and support company deployment in priority markets.
New countries and new markets
Expand commercial presence, develop customer relationships and support market entry and regional business development.
Wellvax · Investor presentation 2026
Restore flow. Reduce operating friction.
Production flow recovery
Targeted scale removal helps restore productivity index and hydrocarbon inflow where mineral deposits restrict flow.
Fewer corrective workovers
Reducing scale accumulation supports less unplanned intervention, less rig time and lower deferred production.
Longer artificial-lift service life
Controlling deposits reduces scale-related wear in electrical submersible pumps and rod-pump systems.
Lower operating burden
Reduced backpressure can lower pumping-energy demand and maintenance costs, supporting improved extraction economics.
Benefits described in the supplied technical sheets. Treatment selection depends on deposit composition and operating conditions.
Wellvax · Investor presentation 2026
The technology and commercial opportunity.
What makes the portfolio distinctive?
Three proprietary systems address different mineral-scale compositions and metallurgy requirements, including carbonate/sulfate mixtures and difficult barite deposits.
Are letters of intent available?
Yes. Letters of intent are in place in Venezuela, the United States, Ecuador and Mexico. They will be provided once negotiations advance and an NDA is signed.
What will the investment fund?
Company expansion, product testing, engineers and technicians, additional personnel, offices, operational deployment and entry into new countries and markets.
How does the base revenue model work?
Five treatments per month × 25,000 litres × an estimated USD 12 per litre equals USD 1.5 million monthly revenue, or USD 18 million annual run-rate. These are model assumptions, not historical sales.
Wellvax · Investor presentation 2026
Match the chemistry to the well.
When is DuoSolve-D the right choice?
For rapid removal of carbonates, anhydrite and sulfates where the well metallurgy permits an acid-based treatment. The single-stage formulation combines carbonate and sulfate dissolution.
When should the alkaline variant be used?
DuoSolve-D Alkaline addresses the same scale families where corrosion risk or sensitive metallurgy calls for a controlled-corrosion chelation system, including 13Cr, duplex and CRA completions.
What makes BaSolve-D Alkaline different?
It is designed to disrupt the highly resistant barite crystal lattice. It can be applied alone or combined with a DuoSolve-D system where barite coexists with other scale deposits.
How are the chemicals integrated into field operations?
The portfolio supports established application methods, including direct injection, coiled tubing, soaking, circulation and squeeze treatments. Product selection follows mineralogy, metallurgy and operating conditions.
Wellvax · Investor presentation 2026
Explore the technology. Advance the opportunity.
- Meet management · Discuss the technology, priority markets and proposed USD 2M / 5% investment.
- Review product applications · Match the three chemical systems to relevant well conditions and customer opportunities.
- Advance under NDA · Review letters of intent and supporting technical and commercial documentation as negotiations progress.
- Agree the growth plan · Define testing, recruitment, offices and market-deployment milestones.
- Finalize the investment · Complete the agreed review and definitive documentation.
Confidential and for the intended recipient only. This is an introduction to an opportunity, not a public offer of securities, investment advice, or a binding commitment. Financial figures are illustrative model assumptions, not guaranteed results or returns. Final investment terms are subject to legal documentation and due diligence.
Wellvax Oilfield Chemical Technologies · Investor presentation 2026